Comparison of percentage IPF and A-IPF for ITP patients and controls in this study and other studies reported in the literature
| . | Controls . | ITP patients . | ||
|---|---|---|---|---|
| IPF, %, mean (range) . | A-IPF, × 109/L, mean (range) . | IPF, %, mean (range) . | A-IPF, × 109/L, mean (range) . | |
| Current study (control, n = 108; ITP, n = 41) | 3.3 (0.5-7.9) | 8.0 (2.6-17.2) | 25.5 (3.5-67.2) | 5.0 (0.3-32.3) |
| Briggs et al37 (control, n = 50; ITP, n = 22) | 3.4 (1.1-6.1) | 8.6 (3.1-16.4) | 19.5 (2.3-52.1)* | 8.1 (1.6-38.6)* |
| Pons I et al39 (control, n = 14; ITP, n = 20) | 2.6 (95% CI, 1.7-3.4) | NA | 16.8 (95% CI, 12.2-21.4) | NA |
| Abe et al46 (control, n = 129; ITP, n = 46) | 3.3 (1.0-10.3) | 7.5 (1.8-25.2) | 17.4 (1.2-53.2) | 4.0 (0.3-19.7) |
| Cannavo et al47 | 2.2 (1.0-4.5) | NA | Median, 11.8 (5.3-54.3) | NA |
| Jung et al48 (control, n = 2039; ITP, n = 150) | 1.1 Male (0.5-3.2) | NA | 7.7 (1.0-33.8) | NA |
| Female (0.4-3.0) | ||||
| Cho et al49 (control, n = 142; ITP, n = 14) | 1.7 (0.4-5.4) | NA | 12.5 | NA |
| . | Controls . | ITP patients . | ||
|---|---|---|---|---|
| IPF, %, mean (range) . | A-IPF, × 109/L, mean (range) . | IPF, %, mean (range) . | A-IPF, × 109/L, mean (range) . | |
| Current study (control, n = 108; ITP, n = 41) | 3.3 (0.5-7.9) | 8.0 (2.6-17.2) | 25.5 (3.5-67.2) | 5.0 (0.3-32.3) |
| Briggs et al37 (control, n = 50; ITP, n = 22) | 3.4 (1.1-6.1) | 8.6 (3.1-16.4) | 19.5 (2.3-52.1)* | 8.1 (1.6-38.6)* |
| Pons I et al39 (control, n = 14; ITP, n = 20) | 2.6 (95% CI, 1.7-3.4) | NA | 16.8 (95% CI, 12.2-21.4) | NA |
| Abe et al46 (control, n = 129; ITP, n = 46) | 3.3 (1.0-10.3) | 7.5 (1.8-25.2) | 17.4 (1.2-53.2) | 4.0 (0.3-19.7) |
| Cannavo et al47 | 2.2 (1.0-4.5) | NA | Median, 11.8 (5.3-54.3) | NA |
| Jung et al48 (control, n = 2039; ITP, n = 150) | 1.1 Male (0.5-3.2) | NA | 7.7 (1.0-33.8) | NA |
| Female (0.4-3.0) | ||||
| Cho et al49 (control, n = 142; ITP, n = 14) | 1.7 (0.4-5.4) | NA | 12.5 | NA |
NA indicates not applicable because this value was not measured in the study.
The means were taken as an average of those reported (platelet > 50 × 109/L: IPF% 16.8%; A-IPF 7.8 × 109/L and platelet < 50 × 109/L: IPF% 22.3%; A-IPF 8.1 × 109/L).